BioCentury

Type: Company

Name: BioCentury

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Biotechnology in Korea and Japan

To ensure that BBSRC Science remains at the frontier of international competitiveness, I arrange occasional visits abroad, approximately annually, to check this out on the ground (one such was the Big Data mission to the USA ). Given the strategic ... [Published Professor Douglas Kell's blog - May 13 2013]

Entities: Industrial Biotechnology Corporation, Biotechnology, Japan

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Merck & Co Inc

Merck’s latest Type 2 diabetes deal uses innovative enzyme selection tech

The ongoing effort to develop better drugs to address the $250 billion problem of Type 2 diabetes has a new development. Merck ( NYSE: MRK ) is collaborating with Abide Therapeutics on three drugs based on a technology platform that selectively chooses ... [Published MedCity News - May 02 2013]

Entities: Merck & Co Inc, Enzyme, Diabetes Type II, Serine, Drugs

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future ... [Published I Am Biotech - Apr 25 2013]

Entities: Jonathan Blum, Affordable Care Act, Medicare, treatments, BioCentury

First reported Mar 29 2013 - Updated Mar 29 2013 - 1 reports

Genentech Inc

Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

A corresponding webcast of the presentation can be accessed by visiting:http://www.media-server.com/m/p/ugxhv6ahThe presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be ... [Published Stockwatch - Mar 29 2013]

Entities: Curis Incorporated, BioCentury, Biotechnology, Genentech Inc, Roche Holding AG

First reported Mar 25 2013 - Updated Mar 25 2013 - 1 reports

The FDA's New Alzheimer's Guidance: Wonder or Blunder?

You can get either answer, depending on whom you ask. Last month, the agency unveiled new guidelines for developing Alzheimer's therapies. They're trying to deal with the difficulty of showing actual cognitive improvement in more advanced patients, ... [Published In the Pipeline - Mar 25 2013]

Entities: Alzheimer's Disease, Drugs, Biomarker, Clinical trials, BioCentury

First reported Mar 13 2013 - Updated Mar 13 2013 - 1 reports

Fosamax

Pharmalot… Pharmalittle… Good Morning

Rise and shine, everyone. Another busy day is on the way. ‘Tis the middle of the week, after all. And you know what that means – a cup of stimulation in each hand. Yes, indeed, we are quaffing at a rapid pace this morning as we attempt to keep up with ... [Published Pharmalot - Mar 13 2013]

Entities: BioCentury, Guillain-Barré Syndrome, Fosamax

First reported Mar 01 2013 - Updated Mar 01 2013 - 1 reports

Pharmalot… Pharmalittle… The Weekend Nears

And so, another working week will soon draw to a close. Not a moment too soon, yes? As you know, this is our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. We hope to catch up on some reading, take a nap or ... [Published Pharmalot - Mar 01 2013]

Entities: BioCentury, Abilify, GOUT, Pursuit

First reported Feb 13 2013 - Updated Feb 13 2013 - 1 reports

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today ,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury ... [Published I Am Biotech - Feb 13 2013]

Entities: Multiple Myeloma, Carfilzomib, Multiple Myeloma Research Foundation, myeloma

First reported Dec 11 2012 - Updated Dec 11 2012 - 1 reports

Free To Promote Off-Label? Not So Fast. . .

Steve Usdin at BioCentury has a very interesting article (free access) following up on that surprise decision that the FDA's restrictions on off-label promotion are a violation of the First Amendment: But companies and individuals who take the ... [Published In the Pipeline - Dec 11 2012]

Entities: BioCentury, First Amendment, Conviction, Supreme Court

Quotes

Videoübertragungen von der EuroMedtech 2013, darunter das Eröffnungsplenum mit dem Titel "Innovation: Wie Entwicklungen im Bereich Finanzen, Strategie und Kooperation die medizintechnische Maschinerie antreiben" stehen unter http://www.partnering360.com/insight zur Verfügung

EuroMedtech™ 2013 fördert Möglichkeiten zur Kooperation, um medizintechnische Innovation auf den ... [Published FinanzNachrichten.de - May 17 2013]

Video coverage of EuroMedtech 2013, including the Opening Plenary "Inside innovation: How developments in financing, strategy and collaboration are driving the medtech machine" can be viewed on http://www.partnering360.com/insight

EuroMedtech™ 2013 Helps Create Collaborative Pathways to Getting Medtech Innovation to Market [Published Business Wire - May 16 2013]

"We are putting the finishing touches on this year's conference and want to make sure as many people as possible have the opportunity to attend" said Brandi Roberts, Chief Financial Officer of Mast Therapeutics, Inc. and the 2013 National Conference Chair

Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 N ... [Published Yahoo! Finance - May 16 2013]

...of the excellence of their partneringONE solution from our experience working with them on BioSpain," said Regina Revilla, President of ASEBIO. "When we originally conceived of BIOLATAM, we knew the importance of having a seamless partnering component, and it just made sense to work with EBD Group."

EBD Group’s partneringONE® to Facilitate Partnering at the First Edition of BIOLATAM in Bogota, C ... [Published Business Wire - May 14 2013]

More Content

sort by: Date \| Relevance
EuroMedtech™ 2013 fördert Möglichkeiten zur Koo... [Published FinanzNachrichten.de - May 17 2013]
EuroMedtech™ 2013 Helps Create Collaborative Pa... [Published Business Wire - May 16 2013]
Registration Extended Until May 22 for Associat... [Published Yahoo! Finance - May 16 2013]
EBD Group’s partneringONE® to Facilitate Partne... [Published Business Wire - May 14 2013]
Chief Executive's blog: Biotechnology in Korea ... [Published BBSRC - May 13 2013]
Biotechnology in Korea and Japan [Published Professor Douglas Kell's blog - May 13 2013]
Producing Orally Bioavailable Biologics [Published Drug Discovery and Development - May 07 2013]
Collaboration between SwedenBIO and the EBD Gro... [Published MyNewsDesk - May 06 2013]
Merck’s latest Type 2 diabetes deal uses innova... [Published MedCity News - May 02 2013]
The Affordable Care Act is Here to Stay [Published I Am Biotech - Apr 25 2013]
Venture Capital Trends [Published I Am Biotech - Apr 24 2013]
Return of BioPharm America™ 2013 to Boston Will... [Published BioPortfolio - Apr 18 2013]
Researchers at Korea Advanced Institute of Scie... [Published Equities.com - Apr 17 2013]
Pharma and Biotech Executives Lead Program at C... [Published Pharmacy Choice - Apr 17 2013]
Medtech-Führungskräfte verraten bei ... [Published PHP Developer's Journal - Apr 13 2013]
Medtech-Führungskräfte verraten bei Podiumsdisk... [Published FinanzNachrichten.de - Apr 12 2013]
Vanda Pharmaceuticals to Present at the BioCent... [Published PR Newswire: Health - Apr 05 2013]
BioCentury & Thomson Reuters to Convene the 20t... [Published Marketwire - Breaking News Releases - Apr 03 2013]
Oncothyreon to Present at Future Leaders in the... [Published PR Newswire: Health - Mar 29 2013]
Curis to Present at the BioCentury Future Leade... [Published GlobeNewswire: Advertising News - Mar 29 2013]
Curis to Present at the BioCentury Future Leade... [Published Stockwatch - Mar 29 2013]
Celladon Corporation To Present at BioCentury F... [Published PR Newswire: General Business - Mar 29 2013]
Sucampo Pharmaceuticals to Present at 20th Annu... [Published Business Wire Science: Science News - Mar 29 2013]
Sucampo Pharmaceuticals to Present at 20th Annu... [Published Business Wire Health News - Mar 29 2013]
ImmunoCellular Therapeutics to Present at Futur... [Published Business Wire Health News - Mar 28 2013]
The FDA's New Alzheimer's Guidance: Wonder or B... [Published In the Pipeline - Mar 25 2013]
EuroMedtech™ 2013 program features medical devi... [Published Pharmalicensing - Mar 20 2013]
Pharmalot… Pharmalittle… Good Morning [Published Pharmalot - Mar 13 2013]
Eisai Is Simply ‘Appalled’ At German Regulators [Published Pharmalot - Mar 08 2013]
Pharmalot… Pharmalittle… The Weekend Nears [Published Pharmalot - Mar 01 2013]

Blogs

sort by: Date \| Relevance
Biotechnology in Korea and Japan [Published Professor Douglas Kell's blog - May 13 2013] To ensure that BBSRC Science remains at the frontier of international competitiveness, I arrange occasional visits abroad, approximately annually, to check this out on the ground (one such was the Big Data mission to the USA ). Given the strategic ...
The Affordable Care Act is Here to Stay [Published I Am Biotech - Apr 25 2013] The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future ...
Venture Capital Trends [Published I Am Biotech - Apr 24 2013] With industry data and numbers, results are always a mixed bag, says David Thomas, BIO’s Director of Industry Research & Analysis – and the latest on venture capital trends is no exception. In the U.S., biotech VC funding is flat, and start-up money ...
The FDA's New Alzheimer's Guidance: Wonder or B... [Published In the Pipeline - Mar 25 2013] You can get either answer, depending on whom you ask. Last month, the agency unveiled new guidelines for developing Alzheimer's therapies. They're trying to deal with the difficulty of showing actual cognitive improvement in more advanced patients, ...
Pharmalot… Pharmalittle… Good Morning [Published Pharmalot - Mar 13 2013] Rise and shine, everyone. Another busy day is on the way. ‘Tis the middle of the week, after all. And you know what that means – a cup of stimulation in each hand. Yes, indeed, we are quaffing at a rapid pace this morning as we attempt to keep up with ...

Press Releases

sort by: Date \| Relevance
EuroMedtech™ 2013 Helps Create Collaborative Pa... [Published Business Wire - May 16 2013]
EBD Group’s partneringONE® to Facilitate Partne... [Published Business Wire - May 14 2013]
Vanda Pharmaceuticals to Present at the BioCent... [Published PR Newswire: Health - Apr 05 2013]
BioCentury & Thomson Reuters to Convene the 20t... [Published Marketwire - Breaking News Releases - Apr 03 2013]
Oncothyreon to Present at Future Leaders in the... [Published PR Newswire: Health - Mar 29 2013]